Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
-
GLP-3R (Retatrutide) is a triple-hormone agonist that achieved up to 28.7% weight loss in Phase 3 TRIUMPH-4, surpassing GLP-1 drugs with fewer reported side effects.
-
Multiple Phase 3 trials, including TRIUMPH-1 through 6 and TRANSCEND-T2D-1, target obesity, diabetes, and cardiovascular conditions, with most results expected through 2026.
-
Patients can pursue access through clinical trials by using ClinicalTrials.gov, meeting BMI and health criteria, and completing screening, while accepting placebo risk and time commitments.
-
Compounded GLP-3R through Mirror Plastic Surgery offers immediate access with personalized dosing, lab monitoring, and 24/7 support under direct medical supervision.
-
Mirror Plastic Surgery delivers concierge-level metabolic care with expert protocols and close follow-up, so patients can pursue meaningful, sustainable health changes.
How GLP-3R (Retatrutide) Works in Your Metabolism
GLP-3R, scientifically known as Retatrutide (LY3437943), represents the next generation of metabolic therapy. Unlike single-target GLP-1 medications, this triple agonist activates three critical hormone pathways at the same time.
-
GLP-1 receptors: Control appetite and slow gastric emptying
-
GIP receptors: Enhance insulin sensitivity and glucose metabolism
-
Glucagon receptors: Increase energy expenditure and fat burning
This combined mechanism addresses insulin resistance, supports significant weight loss, and promotes cardiovascular health while potentially causing less muscle wasting than traditional GLP-1 therapies. These theoretical advantages now connect to real-world outcomes through large Phase 3 trials.
Key GLP-3R Clinical Trial Results in 2026
The following table summarizes the most significant Phase 3 GLP-3R trials. It shows how completed studies compare with ongoing research across obesity, diabetes, and cardiovascular outcomes.
|
Trial |
NCT Number |
Status (April 2026) |
Key Results |
|---|---|---|---|
|
TRIUMPH-4 |
NCT05869903 |
Completed |
28.7% weight loss (12mg), 75.8% pain reduction |
|
TRIUMPH-1 |
NCT05929066 |
Ongoing |
Results expected Q2 2026 |
|
TRANSCEND-T2D-1 |
NCT06354660 |
Completed |
2.0% A1C reduction, 16.8% weight loss |
TRIUMPH-4 delivered unprecedented weight loss, with participants losing an average of 71.2 pounds over 68 weeks. Beyond the raw percentages, these changes often translate into easier movement, less joint pain, and greater day-to-day comfort.
TRANSCEND-T2D-1 highlighted powerful diabetes control, with A1C reductions up to 2.0% alongside meaningful weight loss. This combination suggests strong potential for patients managing both weight and blood sugar.
“These trials signal real-world transformation potential,” notes Ellie Pranckevicius, FNP-BC at Mirror Plastic Surgery. “What excites me most is the comprehensive metabolic improvement, including enhanced insulin sensitivity, reduced inflammation, and better cardiovascular markers.”
Retatrutide Phase 3 Trials: Status, Focus, and Eligibility
Seven Phase 3 TRIUMPH trials are active, with most projected to complete by Q2 to Q3 2026. Each trial focuses on a specific patient group or health condition.
-
TRIUMPH-1, 2, 3: Weight management in obesity, with completion expected in Q2 2026
-
TRIUMPH-5: Obesity with type 2 diabetes, projected completion in Q2 to Q3 2026
-
TRIUMPH-6: Obesity with heart failure, projected completion in Q3 2026
-
TRIUMPH CVOT: Cardiovascular outcomes, with longer follow-up into 2027 and 2028
General eligibility often includes BMI of at least 27 kg/m², or at least 23.5 kg/m² with qualifying health conditions, age between 18 and 75, and specific diagnoses depending on the trial. Typical exclusions include active gastrointestinal disease, a history of pancreatitis, or significant kidney or liver dysfunction.
Understanding these criteria helps patients decide whether trial participation fits their health status and timeline, or whether a supervised compounded option may better match their goals.
How to Enroll in a Retatrutide Clinical Trial
Patients can follow a clear process to explore enrollment in a retatrutide clinical trial.
-
Search ClinicalTrials.gov: Enter terms such as “retatrutide” or “GLP-3R clinical trials.”
-
Filter by location: Select “recruiting” status and narrow results to your region.
-
Review eligibility: Confirm BMI requirements, health conditions, and exclusion criteria.
-
Contact study sites: Reach out to listed locations to request a screening visit.
-
Complete screening: Undergo medical evaluation and the informed consent process.
Clinical trials involve randomization, so some participants receive placebo instead of active medication. Enrollment can take months, and frequent in-person visits are usually required throughout the study. These factors often guide patients to consider compounded alternatives when they want faster access and more predictable treatment.
Compounded GLP-3R with Mirror: Access Trial-Level Benefits Sooner
Compounded GLP-3R offers an option for patients who prefer not to wait for trial placement or future FDA approval. Mirror Plastic Surgery provides immediate access to GLP-3R compounding through personalized, medically supervised protocols.
Our approach differs from unsupervised online sources because we deliver true clinical oversight rather than simple product sales. Ellie Pranckevicius, FNP-BC, combines aesthetic medicine experience with critical care training from Tampa General Hospital’s Neuroscience ICU. This background supports early recognition of metabolic complications and careful dose adjustments.
The compounded GLP-3R protocol includes several structured components.
-
Comprehensive lab analysis, including thyroid function, diabetes markers, and lipid panels
-
Personalized dosing based on individual response and tolerance
-
Quality-assured peptides from reputable suppliers with batch testing
-
24/7 text support and regular telemedicine check-ins
-
Thoughtful combination with other peptide therapies when appropriate
Schedule your metabolic assessment with Ellie to explore GLP-3R compounding that aligns with your health history and goals, without trial delays or placebo uncertainty.
Why Patients Choose Mirror Plastic Surgery for GLP-3R Care
Mirror Plastic Surgery’s concierge model focuses on individualized metabolic care rather than high-volume prescribing. Each journey starts with a 30 to 60 minute consultation with Ellie that reviews medical history, medications, lifestyle, and specific goals.
After lab results return, Ellie designs a tailored protocol that may pair GLP-3R compounding with complementary peptides such as BPC-157 for inflammation or NAD for cellular energy. This stepwise approach connects your lab data to a clear treatment plan.
Patients frequently report early changes such as reduced appetite, improved energy, and less joint pain, followed by steady fat loss and better overall well-being over time. Mirror provides ongoing support and dose adjustments so patients do not feel left on their own.
The practice follows evidence-based medicine under the leadership of Harvard-educated plastic surgeon Dr. Akash Chandawarkar, with Ellie’s dual expertise in aesthetics and critical care supporting safety. The team limits patient volume to maintain close follow-up and responsive communication.
Risks, Safety Oversight, and FDA Timeline
Compounded peptides, including GLP-3R, are not FDA-regulated medications. Mirror Plastic Surgery addresses this by using comprehensive screening, structured dosing protocols, and continuous monitoring.
Clinical trial data shows discontinuation rates of 12 to 18 percent due to side effects, which appear lower than many GLP-1 medications. Most patients experience mild, temporary symptoms during dose escalation. The triple-agonist mechanism distributes metabolic effects across three pathways, which may support improved tolerability.
FDA approval for branded retatrutide is projected for late 2027, following an anticipated New Drug Application submission in Q4 2026. Until then, compounded GLP-3R remains an off-label option that requires careful medical supervision.
Frequently Asked Questions
What are the current retatrutide Phase 3 results?
Phase 3 TRIUMPH-4 results show 28.7 percent weight loss at the 12 mg dose over 68 weeks, along with a 75.8 percent reduction in knee pain scores and improvements in cardiovascular risk markers. Six additional Phase 3 trials are ongoing, with more data expected throughout 2026.
How does GLP-3R compare to GLP-1 for side effects?
GLP-3R appears to cause fewer gastrointestinal side effects than many traditional GLP-1 medications, likely due to its triple-agonist mechanism. Glucagon receptor activation may also help preserve lean mass while enhancing fat burning and energy expenditure.
How can I sign up for retatrutide clinical trials?
Visit ClinicalTrials.gov and search for “retatrutide” or “GLP-3R” to locate active recruiting studies. Filter by your location, review eligibility criteria, and contact study sites directly to request screening. Remember that participation often includes randomization and possible placement in a placebo group.
Is compounded GLP-3R safe without FDA approval?
Compounded GLP-3R is not FDA-approved, so safety depends heavily on medical oversight, screening, and product quality. Mirror Plastic Surgery uses vetted suppliers with batch testing and provides ongoing monitoring to reduce risks and support positive outcomes.
What results can I expect with Mirror’s GLP-3R protocols?
Results vary, but many patients notice early changes within the first week, such as reduced appetite and initial water weight loss. Over the following months, patients often experience significant fat loss, better energy, improved sleep, and stronger metabolic markers when they follow the full protocol.
Where is compounded GLP-3R from Mirror available?
Compounded GLP-3R is currently available through qualified medical providers such as Mirror Plastic Surgery. Mirror offers remote consultations and shipping throughout the United States, including Hawaii and Alaska, so patients can access care regardless of location.
Next Steps with GLP-3R at Mirror Plastic Surgery
GLP-3R represents a major shift in metabolic medicine, pairing powerful weight loss with broad metabolic benefits. While clinical trials continue and branded approval remains several years away, Mirror Plastic Surgery already offers carefully supervised compounded GLP-3R protocols.
Start your transformation today and explore how a personalized GLP-3R plan with Ellie can support your metabolic health and long-term goals.
Contact Information:
Phone: 727-361-6515
Email: hello@mirrorplasticsurgery.com
Address: 780 4th Ave S, St. Petersburg, FL 33701
Instagram: @mirrorplasticsurgery
Request a tailored peptide consultation with Ellie for support with inflammation, weight management, and anti-aging optimization.
Disclaimer: Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Disclaimer: Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
